Oral transmucosal fentanyl citrate for the treatment of breakthrough pain

被引：0
|
作者：
Zarth, R.
Ehmer, M.
Sittig, H. -B.
机构：
[1] Univ Tubingen, Akad Lehrkrankenhaus, Zollernalb Klinikum, Anaesthesiol & Intens Med Abt, D-72336 Balingen, Germany
[2] Praxis Schemerztherapie & Palliativ Med, Freiburg, Germany
[3] Spezielle Schmerztherapie Palliativ Med, MVZ Buntenskamp, Geesthacht, Germany
来源：
SCHMERZ | 2007年 / 21卷 / 06期
关键词：
cancer-related pain; breakthrough pain; oral transmucosal fentanyl citrate; observational study;
D O I：
10.1007/s00482-007-0590-z
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.
引用
收藏
页码：545 / 552
页数：8
相关论文
共 50 条
  • [41] Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis
    Jandhyala, Ravi
    Fullarton, John
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2012, 2 (02) : 156 - 162
  • [42] Oral transmucosal fentanyl and sufentanil for incident pain
    Gardner-Nix, J
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 22 (02) : 627 - 630
  • [43] FENTANYL ABSORPTION IS INFLUENCED BY THE SUGAR MATRIX FORMULATION OF ORAL TRANSMUCOSAL FENTANYL CITRATE
    LIND, GH
    STREISAND, JB
    HAGUE, BI
    BARRUS, BK
    VANDEROORD, B
    STANLEY, TH
    ANESTHESIOLOGY, 1995, 83 (3A) : A299 - A299
  • [44] Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate
    Darwish, Mona
    Kirby, Mary
    Robertson, Philmore, Jr.
    Tracewell, William
    Jiang, John G.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (03): : 343 - 350
  • [45] Efficacy and patient preference for intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain - an open-label crossover trial
    Mercadante, S.
    Popper, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 254 - 254
  • [46] Multicenter, double-blind, randomized comparison of oral transmucosal fentanyl citrate (OTFC) vs. placebo in cancer patients with breakthrough pain
    Rauck, R
    Farrar, J
    Homesley, H
    Busch, M
    ANESTHESIOLOGY, 1997, 87 (03) : A748 - A748
  • [47] Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study
    Hanks, GW
    Nugent, M
    Higgs, CMB
    Busch, MA
    PALLIATIVE MEDICINE, 2004, 18 (08) : 698 - 704
  • [48] Dose proportionality of oral transmucosal fentanyl citrate in human volunteers
    Streisand, JB
    Busch, MA
    Gaylord, BL
    Gay, MA
    East, KA
    ANESTHESIOLOGY, 1996, 85 (3A) : A322 - A322
  • [49] Patients and caregivers' satisfaction with transmucosal fentanyl citrate formulation for breakthrough pain treatment in cancer: prospective, observational study at the university hospital in Grenoble
    Des Courieres, S. Barbou
    Baudrant, M.
    Beziaud, N.
    Maindet, C.
    Durand, A.
    Allenet, B.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (01) : 167 - 167
  • [50] Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate
    Kharasch, ED
    Hoffer, C
    Whittington, D
    ANESTHESIOLOGY, 2004, 101 (03) : 738 - 743
12345